(Q63813257)

English

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE® (Empagliflozin, 10mg, 25mg, q.d.) in Korean Patients With Type 2 Diabetes Mellitus (English)

0 references

0 references

0 references

10 August 2016

0 references

end time

30 June 2019

0 references

number of participants

3,000

0 references

research intervention

empagliflozin

0 references

minimum age

19 year

0 references

maximum age

110 year

0 references

study type

observational study

0 references

Identifiers

ClinicalTrials.gov ID

NCT02848833

0 references

(Q63813257)

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)